June 2019 - Volume 3 - Issue S1 - Contributor Index

Author:
m'sadek, F.
Author:
MA, A.-L.
Author:
Ma, H.

PF612 ONCE-WEEKLY (70 MG/M2) VERSUS TWICE-WEEKLY (56 MG/M2) DOSING OF CARFILZOMIB FOR PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA

Moreau, P.; Stewart, A.K.; Dimopoulos, M.-A.; More

HemaSphere. 3(S1):260, June 2019.

PS1075 ANTITUMOR ACTIVITY OF PEMBROLIZUMAB PLUS DINACICLIB IN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA: THE PHASE 1B KEYNOTE-155 STUDY

Gregory, G.; Walker, P.; Mahadevan, D.; More

HemaSphere. 3(S1):487, June 2019.

Author:
Ma, W.

PF212 NEXT-GENERATION SEQUENCING OF CIRCULATING CELL-FREE DNA PROVIDES COMPLEMENTARY INFORMATION TO GENOMIC PROFILING OF BONE MARROW IN PATIENTS WITH ACUTE LEUKEMIAS

Short, N.; Patel, K.; Albitar, M.; More

HemaSphere. 3(S1):58, June 2019.

Author:
Ma, W.D.

PF272 GLASDEGIB WITH LDAC IN NEWLY DIAGNOSED PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) UNSUITABLE FOR INTENSIVE CHEMOTHERAPY: EFFECTS ON TRANSFUSIONS AND MARROW RECOVERY VS LDAC ALONE

Wang, E.S.; Heuser, M.; Montesinos, P.; More

HemaSphere. 3(S1):87, June 2019.

Author:
Ma, W.W.

PF292 LOW-DOSE CYTARABINE WITH OR WITHOUT GLASDEGIB IN NEWLY DIAGNOSED PATIENTS WITH ACUTE MYELOID LEUKEMIA: LONG-TERM ANALYSIS OF A PHASE 2 RANDOMIZED TRIAL

Papayannidis, C.; Smith, B.D.; Heuser, M.; More

HemaSphere. 3(S1):97-98, June 2019.

PS1029 CLINICAL BENEFIT OF GLASDEGIB PLUS LOW-DOSE CYTARABINE IN PATIENTS WITH DE NOVO AND SECONDARY ACUTE MYELOID LEUKEMIA: LONG-TERM ANALYSIS OF A PHASE 2 RANDOMIZED TRIAL

Heuser, M.; Fiedler, W.; Sekeres, M.A.; More

HemaSphere. 3(S1):464-465, June 2019.

Author:
Ma, X.
Author:
Ma, X.-K.
Author:
Maalej, S.
Author:
Maarek, A.

PS1410 DARATUMUMAB IS WELL TOLERATED AND INDUCES A RAPID HEMATOLOGICAL RESPONSE IN NON IG-M LIGHT CHAIN AMYLOIDOSIS WITH SEVERE CARDIAC IMPAIRMENT

Gounot, R.; Lemonnier, F.; Dupuis, J.; More

HemaSphere. 3(S1):648, June 2019.

Author:
Maarek, O.
Author:
Macartney, C.

PS948 EXCELLENT RESPONSE TO BLINATUMOMAB IN REFRACTORY B LINEAGE ACUTE LYMPHOBLASTIC LEUKAEMIA IN CHILDREN AND YOUNG ADULTS AFTER DEBULKING CHEMOTHERAPY TO ACHIEVE PARTIAL REMISSION

Clesham, K.; Rao, V.; Bartram, J.; More

HemaSphere. 3(S1):427, June 2019.

Author:
MacBeth, K.
Author:
Macdonald, D.

PF614 PATIENT-REPORTED OUTCOMES FROM THE INNOVATE™ STUDY: RESULTS OF IBRUTINIB-RITUXIMAB IN WALDENSTRÖM MACROGLOBULINEMIA (WM)

Tedeschi, A.; Dimopoulos, M.A.; Trotman, J.; More

HemaSphere. 3(S1):260-261, June 2019.

Author:
Mace, S.

S824 A PHASE 3 RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY OF ISATUXIMAB, POMALIDOMIDE, AND LOW-DOSE DEXAMETHASONE VS POMALIDOMIDE AND LOW-DOSE DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

Attal, M.; Richardson, P.G.; Rajkumar, S.V.; More

HemaSphere. 3(S1):365, June 2019.

Author:
MacEwan, D.
Author:
Machado, E.
Author:
Machado, H.B.
Author:
Machado, P.

PB1720 EARLY DEATHS IN ACUTE PROMYELOCYTIC LEUKEMIA: ANALYSIS OF PREDICTIVE FACTORS IN OUR INSTITUTION IN THE LAST 20 YEARS

Raya, J.M.; Rodríguez-Siverio, P.; Rivero-García, M.; More

HemaSphere. 3(S1):791, June 2019.

PS1450 THE PHARMACOLOGICAL IGF1R-IRS1/2 INHIBITOR OSI-906 REDUCES ERYTHROID PROGENITORS AND INHIBITS STAT3 IN JAK2V617F KNOCKIN-MYELOPROLIFERATIVE NEOPLASM MICE

Fernandes, J.C.; Fenerich, B.A.; Coelho-Silva, J.L.; More

HemaSphere. 3(S1):667, June 2019.

Author:
Machalinski, B.
Author:
Machet, A.

PS1406 WEEKLY CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE UNTIL PROGRESSION IN RELAPSED REFRACTORY MULTIPLE MYELOMA

Gruchet, C.; Richez, V.; Guidez, S.; More

HemaSphere. 3(S1):646, June 2019.

Author:
Macheta, M.

S838 TRANSFUSION DEPENDENCY IS ASSOCIATED WITH PRESENCE OF TOXIC IRON SPECIES AND INFERIOR SURVIVAL IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES

Hoeks, M.; Bagguley, T.; Roelofs, R.; More

HemaSphere. 3(S1):373, June 2019.

PS1331 MYELOMONOCYTIC SKEWING IN CHRONIC MYELOMONOCYTIC LEUKEMIA: PHENOTYPIC, GENOTYPIC AND BIOLOGIC FEATURES AND IMPACT ON SURVIVAL

Geissler, K.; Jäger, E.; Barna, A.; More

HemaSphere. 3(S1):607-608, June 2019.

PF414 DNA-BASED BCR-ABL1 ANALYSIS PROVIDES A “TRAFFIC LIGHT” STRATIFICATION MODEL FOR CHRONIC MYELOID LEUKEMIA WITH IMPLICATIONS FOR TREATMENT FREE REMISSION

Machova Polakova, K.; Zizkova, H.; Zuna, J.; More

HemaSphere. 3(S1):159, June 2019.

Author:
Machowicz, R.

PF350 CONSTRUCTION OF A PROGNOSTIC MODEL FOR HLH IN ADULTS – ANALYSIS FROM THE PALG HLH IN ADULTS DATABASE

Machowicz, R.; Staniak, M.; Waszczuk-Gajda, A.; More

HemaSphere. 3(S1):126-127, June 2019.

Author:
Maciag, P.
Author:
Maciejewski, J.

S113 GENETICS AND MODELING OF HUMAN ACUTE ERYTHROID LEUKEMIA

Fagnan, A.; Riera Piqué Borràs, M.; Ignacimouttou, C.; More

HemaSphere. 3(S1):8-9, June 2019.

PS983 NOVEL MOLECULAR PATHOGENESIS AND THERAPEUTIC TARGET IN ACUTE ERYTHROID LEUKEMIA

Takeda, J.; Shih, L.-Y.; Yoshida, K.; More

HemaSphere. 3(S1):442, June 2019.

S135 NGS-BASED COPY-NUMBER ANALYSIS IN MORE THAN 2,000 PATIENTS WITH MYELOID NEOPLASMS

Saiki, R.; Shiozawa, Y.; Yoshizato, T.; More

HemaSphere. 3(S1):19-20, June 2019.

S840 IMPACT OF 1ST LINE TREATMENT ON OVERALL SURVIVAL IN 1.633 PATIENTS WITH CHRONIC MYELOMONOCYTIC LEUKEMIA – A MULTINATIONAL COLLABORATIVE EFFORT COORDINATED BY THE AGMT STUDY GROUP

Pleyer, L.; Leisch, M.; Kouraklis, A.; More

HemaSphere. 3(S1):374-375, June 2019.

Author:
Macintyre, E.

S103 OBINUTUZUMAB PLUS DHAP FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION PLUS OBINUTUZUMAB MAINTENANCE PROVIDES A HIGH MRD RESPONSE RATE IN UNTREATED MCL PATIENTS, LYMA-101 TRIAL - A LYSA TRIAL

Legouill, S.; Beldi-Ferchiou, A.; Cacheux, V.; More

HemaSphere. 3(S1):3, June 2019.

PF151 RAS/MAPK ACTIVATION COOPERATES WITH GAIN OF CHROMOSOME 21 IN B CELL LEUKEMIA AND IS AN ATTRACTIVE TARGET TO IMPROVE THE OUTCOME OF DS CHILDREN WITH B-ALL

Laurent, A.P.; Siret, A.; Ignacimouttou, C.; More

HemaSphere. 3(S1):28, June 2019.

PF175 MULTICENTRE STANDARDIZATION OF MINIMAL RESIDUAL DISEASE DETECTION AND QUANTITATION USING THE EUROCLONALITY-NGS ASSAY

Svaton, M.; Fronkova, E.; Kotrova, M.; More

HemaSphere. 3(S1):39-40, June 2019.

PS1312 QPCR, MFC AND DDPCR: COMPARISON ON MRD SAMPLES FROM THREE PROSPECTIVE TRIALS OF THE EUROPEAN MCL NETWORK

Drandi, D.; Alcantara, M.; Barbero, D.; More

HemaSphere. 3(S1):599, June 2019.

Author:
MacKinnon, R.

PS1155 A PHASE I/II STUDY OF THE SYK INHIBITOR ENTOSPLETINIB IN COMBINATION WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

Kittai, A.; Hashiguchi, T.; Thurlow, B.; More

HemaSphere. 3(S1):524, June 2019.

Author:
Macon, W.
Author:
Macrì, N.

PS1431 IDENTIFICATION OF THE TRUE HYPERDIPLOID MULTIPLE MYELOMA SUBSET BY COMBINING CONVENTIONAL KARYOTYPING AND FISH ANALYSIS

Barila’, G.; Bonaldi, L.; Martines, A.; More

HemaSphere. 3(S1):659, June 2019.

Author:
Macro, M.

S145 PHASE 3 RANDOMIZED STUDY OF DARATUMUMAB + BORTEZOMIB/THALIDOMIDE/DEXAMETHASONE (D-VTD) VERSUS VTD IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: PART 1 CASSIOPEIA RESULTS

Moreau, P.; Attal, M.; Hulin, C.; More

HemaSphere. 3(S1):24-25, June 2019.

PF594 BORTEZOMIB-LENALIDOMIDE-DEXAMETHASONE VS BORTEZOMIB-THALIDOMIDE-DEXAMETHASONE INDUCTION: INTEGRATED ANALYSIS OF RANDOMIZED CONTROLLED TRIALS IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA

Rosiñol, L.; Hebraud, B.; Oriol, A.; More

HemaSphere. 3(S1):249-250, June 2019.

S874 EFFICACY OF DARATUMUMAB + BORTEZOMIB/THALIDOMIDE/DEXAMETHASONE (D-VTD) IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA BASED ON MINIMAL RESIDUAL DISEASE STATUS: ANALYSIS OF CASSIOPEIA

Avet-Loiseau, H.; Moreau, P.; van der Velden, V.H.J.; More

HemaSphere. 3(S1):391-392, June 2019.

Author:
Madalina, S.
Author:
Maddaloni, D.
Author:
Maddocks, K.

PF296 UPDATE OF THE SINGLE-ARM PHASE II L-MIND STUDY OF MOR208 PLUS LENALIDOMIDE IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: HIGH OVERALL RESPONSE RATES IN PATIENT SUBGROUPS WITH POOR PROGNOSIS

Duell, J.; Maddocks, K.; González Barca, E.; More

HemaSphere. 3(S1):100, June 2019.

S866 PHASE 1/2 TRIAL OF ACALABRUTINIB PLUS PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA

Witzig, T.; Maddocks, K.; de Vos, S.; More

HemaSphere. 3(S1):387-388, June 2019.

Author:
Madelaine, I.

PS943 SAFETY AND EFFICACY OF TISAGENLECLEUCEL (CTL019) IN B ACUTE LYMPHOBLASTIC LEUKEMIA IN CHILDREN AND YOUNG ADULTS: ROBERT DEBRÉ AND SAINT LOUIS HOSPITALS EXPERIENCE

Dourthe, M.E.; Cabannes-Hamy, A.; Yakouben, K.; More

HemaSphere. 3(S1):425, June 2019.

PS1219 CAUSES OF NON – ELIGIBILITY FOR CD19 CAR T-CELL IMMUNOTHERAPY IN PATIENTS WITH RELAPSE/REFRACTORY DLBCL. EXPERIENCE OF SAINT-LOUIS HOSPITAL

PAILLASSA, J.; BLASI, R. DI; BERNARD, S.; More

HemaSphere. 3(S1):556, June 2019.

Author:
Madeo, A.

PF533 MUTATIONS ON COHESIN COMPLEX ARE ASSOCIATED TO A POOR PROGNOSIS IN LOW-RISK MYELODYSPLASTIC SYNDROMES PATIENTS

Martín-Izquierdo, M.; López-Cadenas, F.; Sánchez del Real, J.; More

HemaSphere. 3(S1):219-220, June 2019.

Author:
Madkaikar, M.
Author:
Madry, K.

PF350 CONSTRUCTION OF A PROGNOSTIC MODEL FOR HLH IN ADULTS – ANALYSIS FROM THE PALG HLH IN ADULTS DATABASE

Machowicz, R.; Staniak, M.; Waszczuk-Gajda, A.; More

HemaSphere. 3(S1):126-127, June 2019.

Author:
Madzarova, V.
Author:
Maeda, Y.

PS1263 CONSOLIDATION THERAPY USING 90Y-IBRITUMOMAB TIUXETAN AFTER BENDAMUSTINE AND RITUXIMAB IN PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA; A MULTICENTER, PHASE II STUDY (BRIZ2012)

Tsujimura, H.; Miura, K.; Kanno, M.; More

HemaSphere. 3(S1):578, June 2019.

Author:
Maekawa, T.

PS1435 SLAMF7 HIGH CD16 NEGATIVE MONOCYTES INCREASE IN PERIPHERAL BLOOD OF PATIENTS WITH MYELOFIBROSIS IN CORRELATION WITH JAK2V617F MUTATION

Kato, S.; Maekawa, T.; Ogata, K.; More

HemaSphere. 3(S1):661-662, June 2019.

Author:
Maekawa, Y.
Author:
Maertens, J.

PS1283 CLINICAL IMPLICATIONS OF AZOLE-RESISTANT VERSUS AZOLE-SUSCEPTIBLE INVASIVE ASPERGILLOSIS IN HEMATOLOGICAL MALIGNANCY (CLARITY) – A MULTICENTER STUDY

Cornely, O.A.; Seidel, D.; Arenz, D.; More

HemaSphere. 3(S1):587, June 2019.

Author:
Maertens, V.

PF694 TREATMENT-FREE REMISSION AFTER TPO RECEPTOR AGONISTS IN ADULT ITP PATIENTS IN BELGIUM

Janssens, A.; Beguin, Y.; Lambert, C.; More

HemaSphere. 3(S1):301, June 2019.

Author:
Maes, K.